Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Executive Summary

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.


Related Content

Psoriasis Drug Valuation By ICER May Undercut Routine Step Therapy
Multiple Sclerosis Drug Prices Rising By Double-Digits Despite Rebates
Valeant's Brodalumab Faces Conflicting FDA Views On Suicide Risk
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
Rx Spending Growth Won’t Exceed 8% In Coming Years – Express Scripts
CVS Indication-Based Pricing For Cancer Drugs May Roll Out Later In 2016
JAK Inhibitors Start To Come Of Age In Rheumatoid Arthritis
Why There’s Still Room For Sarilumab In RA, According To Sanofi
AstraZeneca Unburdens Itself Of Brodalumab


Related Companies